<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37267521</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-4221</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>International journal of pharmaceutical compounding</Title><ISOAbbreviation>Int J Pharm Compd</ISOAbbreviation></Journal><ArticleTitle>Compounding for the Treatment of COVID-19 and Long COVID, Part 3: The Role of Toll-like Receptors in SARS-CoV-2 Infection and COVID Development.</ArticleTitle><Pagination><StartPage>192</StartPage><EndPage>200</EndPage><MedlinePgn>192-200</MedlinePgn></Pagination><Abstract><AbstractText>Toll-like receptors, which are type I&#xa0;transmembrane proteins and pattern recognition&#xa0;receptors found on cell&#xa0;surfaces and in intracellular membranes,&#xa0;serve as central mediators of both initial&#xa0;innate-immune responses and secondary&#xa0;adaptive/acquired-immune responses.&#xa0;Toll-like receptor 4, the activation of which&#xa0;leads to the synthesis of proinflammatory&#xa0;cytokines and chemokines, has been&#xa0;shown to have a vital role in the innate immune&#xa0;response to severe acute&#xa0;respiratory syndrome coronavirus 2&#xa0;(SARS-CoV-2) infection. In our practice of&#xa0;pharmaceutical compounding, we noted&#xa0;that some individuals with coronavirus disease-&#xa0;2019 (COVID-19) or long COVID&#xa0;achieved limited or no benefit from&#xa0;commercially manufactured treatments&#xa0;designed to alleviate symptoms and&#xa0;enable recovery. We suggest that in such&#xa0;cases, a compounded formulation, which&#xa0;can be easily customized to provide that&#xa0;support, may be of benefit. This article&#xa0;provides a brief review of the ways in&#xa0;which toll-like receptors in general, and&#xa0;toll-like receptor 4 in particular, affect&#xa0;the development and progression of&#xa0;SARS-CoV-2 infection and COVID-19,&#xa0;especially with respect to the human&#xa0;respiratory and central nervous systems&#xa0;and people rendered vulnerable by a&#xa0;comorbid condition (diabetes, obesity)&#xa0;or age. Instructions for compounding 2&#xa0;customized preparations useful in the&#xa0;treatment of COVID-19 and long COVID&#xa0;are also provided.</AbstractText><CopyrightInformation>Copyright&#xa9; by International Journal of Pharmaceutical Compounding, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Riepl</LastName><ForeName>Mike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Retired Compounding Pharmacist, Bismarck, North Dakota. flintlock@bis.midco.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Joe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Dakota PrecisionRx Labs, Bismarck, North Dakota. joe@precisionrxlabs.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Pharm Compd</MedlineTA><NlmUniqueID>9706294</NlmUniqueID><ISSNLinking>1092-4221</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051193" MajorTopicYN="N">Toll-Like Receptors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>16</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37267521</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>